Drugs / 161Tb-SibuDAB
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06343038 Comparator | Feb 2024 → Jun 2028 expected | castration-resistant prostate carcinoma | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 161Tb-SibuDAB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343038 ↗ |
| Route | Intravenous | “Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline” NCT06343038 ↗ |